Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics

CoMFA and CoMSIA based 3D-QSAR of HIV-1 RT wild and mutant (K103, Y181C, and Y188L) inhibitory activities of 4-benzyl/benzoyl pyridin-2-ones followed by protein informatics of corresponding non-nucleoside inhibitors’ binding pockets from pdbs 2BAN, 3MED, 1JKH, and 2YNF were analysed to discover consensus features of the compounds for broad-spectrum activity. The CoMFA/CoMSIA models indicated that compounds with groups which lend steric-cum-electropositive fields in the vicinity of C5, hydrophobic field in the vicinity of C3 of pyridone region and steric field in aryl region produce broad-spectrum anti-HIV-1 RT activity. Also, a linker rendering electronegative field between pyridone and aryl moieties is common requirement for the activities. The protein informatics showed considerable alteration in residues 181 and 188 characteristics on mutation. Also, mutants’ isoelectric points shifted in acidic direction. The study offered fresh avenues for broad-spectrum anti-HIV-1 agents through designing new molecules seeded with groups satisfying common molecular fields and concerns of mutating residues.

[1]  D I Stuart,et al.  Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.

[2]  G. Klebe.  The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. , 1994, Journal of molecular biology.

[3]  D I Stuart,et al.  Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.

[4]  P. Wolschann,et al.  Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives , 2006, SAR and QSAR in environmental research.

[5]  Jens Carlsson,et al.  Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. , 2008, Journal of medicinal chemistry.

[6]  Ravindra K. Rawal,et al.  CP‐MLR/PLS Directed Structure‐Activity Modeling of the HIV‐1 RT Inhibitory Activity of 2,3‐Diaryl‐1,3‐thiazolidin‐4‐ones , 2004 .

[7]  A. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure‐activity relationships III: Modeling hydrophobic interactions , 1988 .

[8]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[9]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[10]  M. T. Barakat,et al.  Molecular structure matching by simulated annealing. I. A comparison between different cooling schedules , 1990, J. Comput. Aided Mol. Des..

[11]  K. Hertogs,et al.  Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. , 2009, Journal of medicinal chemistry.

[12]  C. Hansch,et al.  Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .

[13]  D. Stammers,et al.  Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. , 2008, Virus research.

[14]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[15]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[16]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[17]  Johnson Mak,et al.  Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol , 2006, PLoS pathogens.

[18]  Xiaohong Liu,et al.  Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. , 2010, Journal of medicinal chemistry.

[19]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[20]  Christophe Meyer,et al.  Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. , 2005, Journal of medicinal chemistry.

[21]  Yenamandra S Prabhakar,et al.  2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. , 2005, Bioorganic & medicinal chemistry.

[22]  David S. Wishart,et al.  VADAR: a web server for quantitative evaluation of protein structure quality , 2003, Nucleic Acids Res..

[23]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[24]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .

[25]  M. Michael Gromiha,et al.  CUPSAT: prediction of protein stability upon point mutations , 2006, Nucleic Acids Res..

[26]  Antonio Sillero,et al.  Isoelectric point determination of proteins and other macromolecules: Oscillating method , 2006, Comput. Biol. Medicine.

[27]  Christophe Meyer,et al.  4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. , 2005, Journal of medicinal chemistry.

[28]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[29]  E. De Clercq.  HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase , 1993, Medicinal research reviews.

[30]  J. Humer,et al.  Single HA2 Mutation Increases the Infectivity and Immunogenicity of a Live Attenuated H5N1 Intranasal Influenza Vaccine Candidate Lacking NS1 , 2011, PloS one.

[31]  P. Anderson,et al.  L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase , 1995, Antimicrobial agents and chemotherapy.

[32]  Rajni Garg,et al.  Comparative Quantitative Structure—Activity Relationship Studies on Anti-HIV Drugs , 2000 .

[33]  Liping Wang,et al.  Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2012, Journal of medicinal chemistry.

[34]  S B Katti,et al.  Structure-activity relationship studies on clinically relevant HIV-1 NNRTIs. , 2012, Current medicinal chemistry.

[35]  S Wold,et al.  Multivariate data analysis and experimental design in biomedical research. , 1988, Progress in medicinal chemistry.

[36]  Piero Fariselli,et al.  I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure , 2005, Nucleic Acids Res..

[37]  Arup K. Ghose,et al.  Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics , 1989, J. Chem. Inf. Comput. Sci..

[38]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[39]  R. Paranjape,et al.  Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[40]  Y. S. Prabhakar,et al.  Molecular Surface Features in Modeling the HIV-1 RT Inhibitory Activity of 2-(2,6-Disubstituted phenyl)-3-(substituted pyrimidin-2-yl)-thiazolidin-4-ones , 2007 .

[41]  Twenty years of HIV-1 research: what the future holds , 2003, Nature Immunology.

[42]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[43]  J Zhu,et al.  [Comparative molecular field analysis (CoMFA) of allylamine antimycotics]. , 1997, Yao xue xue bao = Acta pharmaceutica Sinica.

[44]  J. Condra,et al.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors , 1993, Antimicrobial Agents and Chemotherapy.

[45]  Y. S. Prabhakar,et al.  CoMFA and CoMSIA studies on thiazolidin-4-one as anti-HIV-1 agents. , 2009, Journal of molecular graphics & modelling.

[46]  Nan Guo,et al.  PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways , 2006, Nucleic Acids Res..

[47]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[48]  Ravindra K Rawal,et al.  Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. , 2008, European journal of medicinal chemistry.

[49]  Marie-Pierre de Béthune,et al.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.